<SEC-DOCUMENT>0001193125-17-348663.txt : 20171121
<SEC-HEADER>0001193125-17-348663.hdr.sgml : 20171121
<ACCEPTANCE-DATETIME>20171121073333
ACCESSION NUMBER:		0001193125-17-348663
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20171121
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171121
DATE AS OF CHANGE:		20171121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		171215385

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d281870d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>CURRENT REPORT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B></B>Date of Report (Date of earliest event reported):<B> November&nbsp;21, 2017 </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g281870img2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:ARIAL" ALIGN="center"><B>Biogen Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-19311</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0112644</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center">(State or other jurisdiction of incorporation)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Commission File Number)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(IRS Employer Identification No.)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>225 Binney Street, Cambridge, Massachusetts 02142 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Address of principal executive offices; Zip Code) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Registrant&#146;s telephone number, including area code: <B>(617) <FONT STYLE="white-space:nowrap">679-2000</FONT></B> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Former name or former address,
if changed since last report.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT> Soliciting material pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT> <FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> <FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT
STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Emerging growth
company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%" VALIGN="top" ALIGN="left"><FONT COLOR="#0075c9"><B>Item&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#0075c9"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;21, 2017, Biogen Inc. (the &#147;Company&#148;) announced that, in connection with the
appointment of Jeffrey D. Capello as the Company&#146;s Executive Vice President and Chief Financial Officer, Gregory F. Covino, the Company&#146;s Vice President, Finance, Chief Accounting Officer and interim Principal Financial Officer, will step
down as interim Principal Financial Officer effective as of December&nbsp;11, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;21,
2017, the Company announced the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December&nbsp;11, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Mr.&nbsp;Capello, age 53, served as the Chief Financial Officer of Beacon Health Options, Inc., a behavioral health company, with responsibility for finance, human
resources, information technology, real estate and procurement, from October 2016 until November 2017. From July 2015 until September 2016, Mr.&nbsp;Capello was the founder and Chief Executive Officer of Monomoy Advisors which focuses on helping
companies drive shareholder value. From July 2014 until June 2015, Mr.&nbsp;Capello served as the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, an in vitro diagnostics company that was acquired by the Carlyle
Group from Johnson&nbsp;&amp; Johnson, with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, Mr.&nbsp;Capello served as Chief Financial Officer and Executive Vice President of Boston
Scientific Corporation, a worldwide developer, manufacturer and marketer of medical devices, from March 2010 to December 2013. At Boston Scientific, Mr.&nbsp;Capello was responsible for the worldwide management of Boston Scientific&#146;s finance,
information systems, business development and corporate strategy functions. Mr.&nbsp;Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific,
he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc., a life sciences tool company, from 2006 to 2008. Previously, he served as PerkinElmer&#146;s Vice
President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr.&nbsp;Capello was a Partner at PricewaterhouseCoopers LLP, both in the United States and in the Netherlands.
Mr.&nbsp;Capello serves on the Board of Directors of OvaScience, Inc., a biotechnology company, and on the Board of Directors of Flex Pharma, Inc., a biotechnology company. Mr.&nbsp;Capello holds a B.S. degree in Business Administration from the
University of Vermont and an M.B.A. degree from Harvard Business School. Mr.&nbsp;Capello is also a certified public accountant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the terms of an offer letter
that Mr.&nbsp;Capello entered into in connection with his hiring as Executive Vice President and Chief Financial Officer of the Company, his base salary will be $750,000 and, beginning in 2018, he is eligible to participate in the Company&#146;s
annual bonus plan with a target bonus of 70% of his annual base salary. The offer letter also provides that Mr.&nbsp;Capello will receive a <FONT STYLE="white-space:nowrap">one-time</FONT> cash <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus
of $520,000, which will be paid after his start date. Mr.&nbsp;Capello&#146;s <FONT STYLE="white-space:nowrap">one-time</FONT> cash <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is subject to recoupment by the Company as follows: 100% of his
cash <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is subject to recoupment if Mr.&nbsp;Capello&#146;s employment terminates within the first year of his employment; 70% of his cash <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is
subject to recoupment if Mr.&nbsp;Capello&#146;s employment terminates within the second year of his employment; and 35% of his cash <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is subject to recoupment if Mr.&nbsp;Capello&#146;s employment
terminates within the third year of his employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, the offer letter provides that Mr.&nbsp;Capello will be eligible to participate in the Biogen Inc.
2017 Omnibus Equity Plan (the &#147;2017 Plan&#148;) and will receive, under the 2017 Plan, (a)&nbsp;performance stock units with a grant date value of $1,500,000 and (b)&nbsp;market stock units with a grant date value of $1,500,000, each award to
be made on the first trading day of the month following his start date. The performance stock units will convert into shares of the Company&#146;s common stock and cash and will cliff vest after three years based on the achievement of specified
performance goals. The market stock units are performance-based restricted stock units that will convert into shares of the Company&#146;s common stock and are earned based on the growth of the Company&#146;s common stock price from the date of
grant to each of the three annual vesting dates. On each vesting date, the performance multiplier is derived based on the stock price growth measured from the grant date to each of the three annual vesting dates using the average closing stock price
for the 30 calendar days prior to and including the grant date and each vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the existing executive severance plan for Executive Vice Presidents,
Mr.&nbsp;Capello will be entitled to receive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the event of a termination of employment other than for cause and other than by reason of Mr.&nbsp;Capello&#146;s death or disability, he would be entitled to receive a lump sum severance payment equal to a minimum
of twelve months of his then-annual base salary and target annual bonus, with an additional two months for each full year of service to a maximum benefit of 21 months. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If, within two years following a corporate transaction or a corporate change in control, Mr.&nbsp;Capello experiences a termination of employment other than for cause or by reason of death or disability or experiences
an involuntary employment action, he would be entitled to a lump sum severance payment equal to two times his then-annual base salary plus target annual bonus. These payments are in lieu of any payment in the preceding paragraph. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Mr.&nbsp;Capello is also entitled to receive continuation of medical and dental insurance benefits if severance is payable under the severance plan for Executive Vice
Presidents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%" VALIGN="top" ALIGN="left"><FONT COLOR="#0075c9"><B>Item&nbsp;7.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#0075c9"><B>Regulation FD Disclosure. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On November&nbsp;21, 2017, the Company issued a press
release announcing the appointment of Mr.&nbsp;Capello as Executive Vice President and Chief Financial Officer of the Company effective as of December&nbsp;11, 2017. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein
by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The press release being furnished in this Item 7.01 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange
Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%" VALIGN="top" ALIGN="left"><FONT COLOR="#0075c9"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#0075c9"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The exhibit listed on the Exhibit Index below is furnished as part of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:68.30pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit&nbsp;Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:49.95pt; font-size:10pt; font-family:ARIAL">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d281870dex991.htm">Biogen&#146;s press release dated November&nbsp;21, 2017. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B>Signatures </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Biogen Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;/s/ Suzanne Murray</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;Suzanne Murray</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;Assistant Secretary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Date: November&nbsp;21, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d281870dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g281870img1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B>MEDIA CONTACT:</B></FONT></P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Biogen</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Matt Fearer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Ph: +1 781 464 3260</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL"><FONT COLOR="#0000ff"><U>public.affairs@biogen.com</U></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B>INVESTOR CONTACT:</B></FONT></P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Biogen</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Matt Calistri</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Ph: +1 781 464 2442</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL"><FONT COLOR="#0000ff"><U>IR@biogen.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><FONT COLOR="#0075c9"><B>BIOGEN APPOINTS JEFF CAPELLO AS EXECUTIVE VICE PRESIDENT </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><FONT COLOR="#0075c9"><B>AND CHIEF FINANCIAL OFFICER </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>CAMBRIDGE, Mass.&#151; November&nbsp;21, 2017 -- </B>Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and
Chief Financial Officer effective as of December&nbsp;11, 2017.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial">Mr.&nbsp;Capello will lead Biogen&#146;s Business Planning, Tax, Treasury, Internal Audit,
Accounting, and Investor Relations functions. He will report to Michel Vounatsos, CEO of Biogen, will be a member of the Executive Committee, and will be based in Cambridge, Mass. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial">Mr.&nbsp;Capello brings 26 years of experience in finance. Most recently he was Executive Vice President and Chief Financial Officer of Beacon Health Options Inc. His
previous experience includes founding and running his own company, Monomy Advisors, and serving as Chief Financial Officer of Ortho Clinical Diagnostics, Boston Scientific Corporation, and Perkin Elmer. Earlier in his career he was also a partner in
the Boston and Amsterdam offices of PwC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial">Mr.&nbsp;Capello is a certified public accountant. He holds a B.S. in Business Administration from the University of
Vermont and an M.B.A. in Accounting from Harvard Business School. Drafted by the Buffalo Sabres in the National Hockey League, Mr.&nbsp;Capello played two seasons for their American Hockey League club. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial">&#147;I am very excited to join Biogen, a company which is recognized as a pioneer and a leader in treating neurological diseases,&#148; said Mr.&nbsp;Capello. &#147;I
look forward to working with colleagues around the world in our mission to make a difference in the lives of patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial">&#147;We are fortunate to have Jeff
join Biogen given the depth and breadth of his experience,&#148; said Mr.&nbsp;Vounatsos. &#147;He comes to Biogen at an exciting time as we execute our business strategy, pursue business development opportunities and build our pipeline.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>About Biogen </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:arial">At Biogen, our mission is clear: we are pioneers in
neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world&#146;s first global biotechnology companies by
Charles Weissman, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen<B><I> </I></B>has the leading portfolio of medicines </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9">| More |
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><FONT COLOR="#0075c9">P<SMALL>AGE</SMALL>
 2
 | </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial">
to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer&#146;s
disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post
information that may be important to investors on our website at <FONT STYLE="font-family:arial" COLOR="#0000ff">www.biogen.com</FONT><FONT STYLE="font-family:arial">. To learn more, please visit
</FONT><FONT STYLE="font-family:arial" COLOR="#0000ff">www.biogen.com</FONT><FONT STYLE="font-family:arial"> and follow us on social media &#150; </FONT><FONT STYLE="font-family:arial" COLOR="#0000ff">Twitter</FONT><FONT STYLE="font-family:arial">,
</FONT><FONT STYLE="font-family:arial" COLOR="#0000ff">LinkedIn</FONT><FONT STYLE="font-family:arial">, </FONT><FONT STYLE="font-family:arial" COLOR="#0000ff">Facebook</FONT><FONT STYLE="font-family:arial">, </FONT><FONT
STYLE="font-family:arial" COLOR="#0000ff">YouTube</FONT><FONT STYLE="font-family:arial">. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Biogen Safe Harbor </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:arial">This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including
statements relating to our business activities, our strategy and plans, the potential of our commercial business and pipeline programs, and the expected benefits from Mr.&nbsp;Capello&#146;s appointment as Executive Vice President and Chief
Financial Officer. These forward-looking statements may be accompanied by words such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;except,&#148; &#147;forecast,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;possible,&#148; &#147;will,&#148; and other words and terms of similar meaning. You should not place undue reliance on these statements. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:arial">These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without
limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; potential future healthcare reforms; the
occurrence of adverse safety events; failure to protect and enforce our data, intellectual property, and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing,
licensing, or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report
and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g281870img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281870img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@+& P$1  (1 0,1 ?_$ ,@  0 " P$! 0$!
M       ("08'"@4#! $" 0$  @(# 0$             !@<%" ,$"0$"$
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M; : !^/:QP'GBIQ:^#7H&AI&%J;]0*V&Q/F?/)=%_I7[.T7$D_AV<,3Y8*;
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M44C*)+TY9FW]K[S:5B5K0L&%(5EF+6EC!!V8P&(A3,%I,/9?X81&>(!VFN<
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MP[BOS3*7;,&Y'*=%DUT%FI3D*H50VRW;PVF-T8$GJ+3$S+"IPX.RUSG'Y,Q
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MGN"4J^1D;'A7[DZ+>8E[?:O&*;%N4YOU@XB?Z&ACG2H*_P!'7(D]57_B5>%
MBQ:='E7R<J6L+G0V-V=F,]HQ+&O(>7NP_ V+^+  J=:MMY-Z9L4RDQ(T*'4(
M,RR;F0YX:V(]V(=":3@'.8"P,;_ONA_AQ)"K]TH]YK.&D_"]M8*CL<XPORU[
M--)TM1_<#N<@9QA&2\J]FG$<\/$+&:2J24G(KF27,DFM0A_0<Q_32M+1UO\
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MIZ<CR<S$9L.="<6ES<0=DD>8Q .'O"[5;T[0M20&2U>E8,W+PW[36Q&AP:[
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H 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g281870img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281870img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +P"1 P$1  (1 0,1 ?_$ +<   $$ P #
M       %" D*! 8' 0(# 0 !! ,! 0               P8'" ($!0D!$
M!@$# P," @8%#0     ! @,$!08'$1(( !,)(105,18B(T%183(D"G&!0E(7
MD:&Q<H*B,V/3E%<8&1$  0(% @0$! ,& P4)     1$"  ,$!08A$C%!$P=1
M810(<2(R%8&A))'!0B,6%_!28K'1HK,8@C-38S14)54W_]H # ,!  (1 Q$
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MI61CBF(845'"[,[@I=P$*4Q3#(F/^V'*+I9?N-5<)-/73&![))!<6AP4-)!
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2_P!SI/\ F?ZOSC+]/_H_*/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
